title: Cytoprotective efficacy of amifostine against radiation- induced rectal toxicity: objective and subjective grading scales for radiomucositis.
abstract: Curative radiation therapy of pelvic malignancies, frequently results in dose limiting toxicities such as serous, mucoid, or more rarely, bloody diarrhea. Several studies have evaluated the cytoprotective effects of amifostine in preventing rectal mucositis associated with radiation treatment. We searched Medline for published comparative studies that evaluated the use of amifostine to reduce radiation-induced toxicity associated with pelvic irradiation. In ten studies there was an evidence-based cytoprotection (P less than 0.05)by amifostine. Although results are variable, current evidence suggests that amifostine may have a radioprotective effect in the rectal mucosa, particularly when administered intrarectally. Significant improvements were seen in both symptomatic and objective(rectosigmoidoscopy) end points. There is a need to conduct well-designed clinical trials with sufficient numbers of participants to confirm these findings together with a cost benefit study. Objective measurements using rectosigmoidoscopy are superior to subjective measures such as WHO or RTOG/EORTC toxicity grading scales.
authors.affiliation: Kapodistrian University, 2nd Radiology Department, Medical School, Attikon University Hospital, Rimini 1, Xaidari, Greece. vkouloul@cc.ece.ntua.gr
authors.forename: Vassilis E
authors.initials: VE
authors.lastname: Kouloulias
authors.forename: John R
authors.initials: JR
authors.lastname: Kouvaris
mesh_terms: D004999:Amifostine / Q000494:pharmacology*; D019610:Cytoprotection / Q000187:drug effects*; D023381:Endpoint Determination; D006801:Humans; D011827:Radiation; D012002:Rectal Diseases / Q000139:chemically induced*; D016896:Treatment Outcome
chemical_list: D004999:Amifostine